Related Experiment Video

Updated: Jun 3, 2026

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Unveiling the molecular pathogenesis of chordoma: a new paradigm for molecular targeting of rare cancers

Angelo Paolo Dei Tos1

  • 1Departments of Pathology and Oncology, General Hospital of Treviso, Piazza Ospedale 1, Treviso, Italy. apdeitos@ulss.tv.it

The Journal of Pathology
|March 12, 2011
PubMed

Insights

Chordoma, a rare cancer, shows gene copy gains in T (brachyury homologue) and EGFR (epidermal growth factor receptor), driving proliferation. Targeting these offers a new therapeutic strategy for this challenging sarcoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Chordoma is an orphan sarcoma with limited systemic treatment options.
  • Recent research highlights key molecular oncogenesis pathways in chordoma.
  • Understanding chordoma's genetic drivers is crucial for therapeutic development.

Purpose of the Study:

  • To identify actionable molecular targets in chordoma.
  • To provide a preclinical rationale for novel therapeutic strategies.
  • To discuss methodologies for rare cancer clinical trials.

Main Methods:

  • Analysis of gene copy number alterations in chordoma.
  • Investigating the role of specific genes in cell proliferation.
  • Review of clinical trial methodologies for rare cancers.

Main Results:

  • Demonstration of copy number gains for T (brachyury homologue) and EGFR (epidermal growth factor receptor) genes.
  • Evidence supporting the role of T and EGFR in promoting chordoma cell proliferation.
  • Identification of these genes as potential therapeutic targets.

Conclusions:

  • Inhibition of T and EGFR products presents a credible therapeutic strategy for chordoma.
  • Bayesian methodology is suggested for rare cancer clinical trials due to feasibility limitations.
  • Preclinical evidence, like that presented, is vital for establishing prior probabilities in rare cancer trials.

More Related Videos

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Revealing the Ferroptotic Phenotype of Medulloblastoma04:01

Revealing the Ferroptotic Phenotype of Medulloblastoma

Published on: March 15, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...